This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Dermatology Remove Drug Delivery Remove Protein Related Topics
Filler Drug Delivery Systems Genetic Engineering Cosmetics Containment Licensing Clinical Development Genetics Gene Drugs More Related Topics >
article thumbnail

Potential breakthrough in treatment of urea associated skin diseases

Drug Discovery World

DECEMBER 11, 2023

MC2-25 CKD is based on a di-peptide selected to inhibit carbamylation of amino acids and proteins in skin, which is believed to be the causal factor in CKD-aP. The active component of MC2-25 CKD is a di-peptide, which is formulated in cream based on MC2 Therapeutics’ formulation and drug delivery system PAD Technology.

Drug Delivery Systems 52
Drug Delivery Systems Drug Delivery Protein Trials 52
article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40
Licensing Licensing Dermatology Production 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024